BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang X, Luo L, Li Y, Wu H, Hu Q, Yue H, He X, Zou J, Min S. Therapeutic potential of targeting HSPA5 through dual regulation of two candidate prognostic biomarkers ANXA1 and PSAT1 in osteosarcoma. Aging (Albany NY) 2020;13:1212-35. [PMID: 33291071 DOI: 10.18632/aging.202258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang H, Du H, Liu Y, Tian X, Xia J, Yang S. Identification of novel prognostic biomarkers for osteosarcoma: a bioinformatics analysis of differentially expressed genes in the mesenchymal stem cells from single-cell sequencing data set. Transl Cancer Res 2022;11:3841-52. [PMID: 36388032 DOI: 10.21037/tcr-22-2370] [Reference Citation Analysis]
2 Zhang C, Liu Q, Zhou Y, Hua J, Su R, Ai J, Gu C. HSPA5 Could Be a Prognostic Biomarker Correlated with Immune Infiltration in Breast Cancer. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/7177192] [Reference Citation Analysis]
3 Ding C, He R, Zhang J, Dong Z, Wu J. Pseudogene HSPA7 is a poor prognostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) and correlated with immune infiltrates. Cancer Cell Int 2021;21:435. [PMID: 34412642 DOI: 10.1186/s12935-021-02141-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]